Found 27 results in Expert Content

Summary: Our iPSC banks utilize specialized reprogramming technology to transform commercial-use donor consented, clinically approved, cord blood collections into HLA-homozygous lines that are immune compatible with a wide population.

Summary: During this session, we review progress in several areas of advanced development and their impact on readiness for large scale manufacturing.

Summary: In this informative interview with Phacilitate, Boris Greber and Thomas Marx answer questions about the position of induced pluripotent stem cells in today’s advanced therapies market and the transformative power latent in their clinical application.

Summary: In this ebook, we bring you expert insights into the advantages that various cellular starting materials have, with a particular focus on human induced pluripotent stem cells (iPSCs).

Summary: Catalent and RegMedNet showcase how induced pluripotent stem cells can catalyze the advancement of novel cell therapies. This feature explores biological, clinical and commercial characteristics of iPSCs as ideal starting materials.

Summary: How can using iPSCs as starting materials help with transforming cell therapies into standard care? This infographic highlights the key features of iPSCs as starting materials, from donor consent through to commercial innovation.

Summary: This podcast focuses on the specialized needs of manufacturing cell therapies at scale and how Custom Manufacturing Organizations are stepping in to drive process efficiencies and standardization.

Summary: In this presentation, our Expert discusses efforts underway at Catalent to accelerate the path to clinic for iPSC-based therapies.

Summary: Scientists are leading a well-funded drive to adapt technology for solid tumors while making the whole process much more economical for patients and payers.

Summary: At Catalent, we implement innovative manufacturing and fill & finish methodologies to accelerate the path to commercial for MSCs and other allogeneic modalities.